Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Completed · Phase 2/Phase 3

Conditions studied: Blepharitis

In brief

The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles. The hypothesis for the study is the proportion of participants cured at Day 43 with treatment by TP-03, 0.25%, is greater than the proportion cured by treatment with its vehicle.

Key facts

Study ID
NCT04475432
Run by
Tarsus Pharmaceuticals, Inc.
People needed
421
Starts
2020-09-09
Expected to finish
2021-05-04
Last updated by the study team
2023-12-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.